| Hormone refractory prostate cancer
Provenge vs Talzenna
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Provenge vs Talzenna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTalzenna has a higher rate of injection site reactions vs Provenge based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Talzenna but not Provenge, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Provenge
Talzenna
At A Glance
IV infusion
Every 2 weeks
Autologous cellular immunotherapy
Oral
Daily
PARP inhibitor
Indications
- Hormone refractory prostate cancer
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
Dosing
Hormone refractory prostate cancer 3 complete doses at approximately 2-week intervals; each dose infused IV over approximately 60 minutes; premedicate with acetaminophen and antihistamine approximately 30 minutes prior to infusion.
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Chills, fatigue, fever, back pain, nausea, joint ache, headache
Serious Acute infusion reactions, cerebrovascular events, eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, tumor flare
Postmarketing Syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, pulmonary embolism
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Pharmacology
PROVENGE is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers; APCs are activated ex vivo with the PAP-GM-CSF fusion protein, take up and process the recombinant antigen, and display it on the cell surface to stimulate T cell and antibody responses.
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Provenge
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Provenge
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Provenge
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Talzenna.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ProvengeView full Provenge profile
TalzennaView full Talzenna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.